Compare ARK Innovation ETF (ARKK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs BIO-TECHNE Corp — how do they compare? ARK Innovation ETF trades at $80.24, while BIO-TECHNE Corp trades at $72.12 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while ARK Innovation ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKK | TECH | |
|---|---|---|
52-Week High | $92.50 | $72.29 |
52-Week Low | $63.52 | $43.31 |
Market Cap | — | $11.24B |
Sector | — | Health |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $79.43, up 4.89% today with strong technical momentum as moving averages signal bullish alignment. The ETF faces mixed sentiment with recent Seeking Alpha articles highlighting concentration risks in SpaceX and Tesla holdings while Cathie Wood continues aggressive AI stock purchases. Technical indicators show RSI at overbought levels near 82, suggesting potential near-term consolidation despite the bullish trend.
Outlook remains polarized between innovation optimism and valuation concerns. The fund's heavy exposure to speculative tech names offers growth potential but carries significant volatility risk. Recent underperformance versus broad market indices and high fee structure present headwinds, while continued institutional interest in disruptive technologies provides long-term catalysts.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
